Neuralink, Elon Musk’s brain implant company, announced on Thursday that the US Food and Drug Administration (FDA) has given the green light to its first human clinical trials, Reuters reports.

The FDA approval “represents an important first step that will allow our technology to one day help many people,” Neuralink said in a post on its Twitter page.

The neurotechnology research company did not provide details about the purpose of the study, saying only that it is not yet recruiting participants and will announce more soon.

Neuralink and the FDA did not immediately respond to Reuters’ request for comment.

Musk sees brain implants as solutions for a wide range of diseases, including obesity, autism, depression and schizophrenia, as well as for things like web surfing or telepathy.

Elon Musk says he will test Neuralink devices, including on his own children

Late last year, a South African billionaire made headlines when he said he was so confident in the devices’ safety that he would be willing to implant them in his children. At the time, he estimated that Neuralink would connect a human brain to a computer within six months.

Musk has predicted that Neuralink will begin human trials at least four times starting in 2019, but his company did not seek FDA approval until early 2022. The agency rejected the initial request, according to statements several Neuralink employees told Reuters last month in March.

The FDA outlined several issues that Neuralink was required to address before approval for human trials, they said.

The main concerns were the lithium battery of the device, the possibility of the implant wires migrating into the brain, and the possibility of safely removing the device without damaging the brain tissue.

The brain chip research company is under investigation by several US authorities

Neuralink, founded in 2016 by Elon Musk, has been the subject of several federal investigations.

In May, US lawmakers asked regulators to investigate whether the way the committee that oversees animal testing at Neuralink was set up contributed to the rushed experiments that failed.

The Department of Transportation in Washington is conducting a separate investigation into whether Neuralink illegally transported dangerous pathogens on chips extracted from monkey brains without proper safeguards.

Neuralink is also under investigation by the USDA’s Office of Inspector General for possible animal welfare violations.

Neuralink did not respond to requests for comment on these requests.